Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03098550 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT03098550 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 105 participants.
The verdict
NCT03098550, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Daratumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2020-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03098550
The ClinicalTrials.gov registry entry for NCT03098550 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03098550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03098550 about?
NCT03098550 is a clinical study titled "A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread". The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.
What is the current status of trial NCT03098550?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2017-06-15. Estimated completion is 2020-07-06.
What interventions are being tested in trial NCT03098550?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Daratumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03098550?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.